Masakazu Takeuchi

12PUBLICATIONS
21CO-AUTHORS
PharmacogenomicsFood properties (incl. characteristics and health benefits)Pharmaceutical delivery technologiesNutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 27, 2025
Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.

Masato Yoneda, Masakazu Takeuchi, Tomonori Oura

|Feb 07, 2025
Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.

Toshihiko Aranishi, Ataru Igarashi, Kazuo Hara

|Feb 01, 2025
Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.

Hanaka Mimura, Tomonori Oura, Rina Chin

|Dec 21, 2024
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.

Toshihiko Aranishi, Ataru Igarashi, Kazuo Hara

|Aug 28, 2024
Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.

Kazuya Fujihara, Yasuhiro Matsubayashi, Masaru Kitazawa

|May 07, 2024
A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).

Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki

Pageof 2

Frequent Collaborators

7 joint publications

Tomonori Oura

2 joint publications

Barnaby Hunt

2 joint publications

Zhihong Cai

2 joint publications

Ataru Igarashi